Results 51 to 60 of about 3,116,614 (307)

circRNA-SORE/UBQLN1/GPX4 Mediates the Acquisition of Sorafenib Resistance in Hepatocellular Carcinoma Through Inhibition of Ferroptosis. [PDF]

MedComm (2020)
Ji L, Ruan Y, Tong M, Chen T, Cai J, Ye Z, Cai X, Xu J.   +7 more
europepmc   +3 more sources

CRISPR/Cas9 screens unravel miR-3689a-3p regulating sorafenib resistance in hepatocellular carcinoma via suppressing CCS/SOD1-dependent mitochondrial oxidative stress

Drug resistance updates, 2023
Yuanjun Lu, Yau-Tuen Chan, Junyu Wu, Zixin Feng, Hongchao Yuan, Qiucheng Li, Tingyuan Xing, Lin Xu, Cheng Zhang, Hor‐Yue Tan, Terence K. Lee, Yibin Feng, Ning Wang   +12 more
openalex   +2 more sources

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma [PDF]

Journal of Biomedical Science, 2022
Abstract Background Hepatocellular carcinoma (HCC) is the sixth most common type of cancer and has a high mortality rate worldwide. Sorafenib is the only systemic treatment demonstrating a statistically significant but modest overall survival benefit.
You-Liang Lai, Kai-Hung Wang, Hsing-Pang Hsieh, Wan-Ching Yen   +3 more
openaire   +3 more sources

Upregulation of USP22 and ABCC1 during Sorafenib Treatment of Hepatocellular Carcinoma Contribute to Development of Resistance

Cells, 2022
Sorafenib is a small molecule that blocks tumor proliferation by targeting the activity of multi-kinases for the treatment of advanced hepatocellular carcinoma (HCC). Increasing sorafenib resistance following long-term treatment is frequently encountered.
Yung-Sheng Chang, Chien-Wei Su, San-Chi Chen, Yen-Ying Chen, Yuh-Jin Liang, Jaw-Ching Wu   +5 more
doaj   +1 more source

Advancements in elucidating the mechanisms of Sorafenib resistance in hepatocellular carcinoma. [PDF]

Int J Surg
Huang C, Li Y, Zhang F, Zhang C, Ding Z.
europepmc   +2 more sources

Cholesterol sensor SCAP contributes to sorafenib resistance by regulating autophagy in hepatocellular carcinoma

Journal of Experimental & Clinical Cancer Research, 2022
Background Hepatocellular carcinoma (HCC) is one of the most malignant tumors and the fourth leading cause of cancer-related death worldwide. Sorafenib is currently acknowledged as a standard therapy for advanced HCC.
Danyang Li, Yingcheng Yao, Yuhan Rao, Xinyu Huang, Li Wei, Zhimei You, Guo Zheng, Xiaoli Hou, Yu Su, Zac Varghese, John F. Moorhead, Yaxi Chen, Xiong Z. Ruan   +12 more
doaj   +1 more source

Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma

Frontiers in Oncology, 2021
Sorafenib a multi-target tyrosine kinase inhibitor, is the first-line drug for treating advanced hepatocellular carcinoma (HCC). Mechanistically, it suppresses tumor angiogenesis, cell proliferation and promotes apoptosis.
Zhi Zeng, Zhi Zeng, Qiliang Lu, Qiliang Lu, Yang Liu, Yang Liu, Junjun Zhao, Junjun Zhao, Qian Zhang, Linjun Hu, Linjun Hu, Zhan Shi, Yifeng Tu, Zunqiang Xiao, Qiuran Xu, Dongsheng Huang   +15 more
doaj   +1 more source

Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis

Journal of Experimental & Clinical Cancer Research, 2023
Background Sorafenib resistance is a key impediment to successful treatment of patients with advanced hepatocellular carcinoma (HCC) and recent studies have reported reversal of drug resistance by targeting ferroptosis. The present study aimed to explore
Yan Li, Wenjuan Yang, Yuanyuan Zheng, Weiqi Dai, Jie Ji, Liwei Wu, Ziqi Cheng, Jie Zhang, Jingjing Li, Xuanfu Xu, Jianye Wu, Mingwei Yang, Jiao Feng, Chuanyong Guo   +13 more
doaj   +1 more source

The Ribosomal Protein L28 Gene Induces Sorafenib Resistance in Hepatocellular Carcinoma

Frontiers in Oncology, 2021
BackgroundSorafenib is the first molecular-targeted drug for the treatment of advanced hepatocellular carcinoma (HCC). However, its treatment efficiency decreases after a short period of time because of the development of drug resistance.
Yi Shi, Yi Shi, Xiaojiang Wang, Xiaojiang Wang, Qiong Zhu, Gang Chen, Gang Chen   +6 more
doaj   +1 more source

Fucoidan inhibits EGFR redistribution and potentiates sorafenib to overcome sorafenib-resistant hepatocellular carcinoma

Biomedicine & Pharmacotherapy, 2022
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. Although sorafenib is a standard first-line molecule-targeted drug against advanced HCC, the drug resistance development and adverse side effects usually limit its efficacy.
Jialiang, Luo, Lei, Li, Zhengyumeng, Zhu, Bo, Chang, Fan, Deng, Di, Wang, Xiao, Lu, Daming, Zuo, Qingyun, Chen, Jia, Zhou   +9 more
openaire   +2 more sources